AAIC 2023 – Lilly downplays tau testing needs
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
ADA 2023 – Lilly unveils its triple threat
Retatrutide looks like the most powerful obesity agent yet, though side effects will need careful monitoring.
ADA 2023 – Vertex raises hopes of type 1 diabetes cure
But it still has a long way to go with its islet cell therapies.
ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin
A quarter of patients fail to stomach survodutide.
Easl 2023 – Biomarkers back a new Nash player
Boston’s Novartis cast-off looks highly promising versus better-known projects.
Easl 2023 – GLP-1 combos take on a milder form of Nash
Similarly acting agents from Merck & Co and Altimmune aim to improve NAFLD, with mixed results.
Easl 2023 – Madrigal denies pivotal endpoint change
The primary analysis of Maestro-Nash had always relied on Nafld activity score, with a controversial trial entry change just a “typo”, the company says.
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
Weight loss with Lilly’s oral GLP-1 agonist orforglipron falls short of the previously revealed “mid-teens” benchmark.